Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 143, Issue 12, pp 2571–2579 | Cite as

Identification of prognostic markers of high grade prostate cancer through an integrated bioinformatics approach

  • Hai Huang
  • Qin Zhang
  • Chen Ye
  • Jian-Min Lv
  • Xi Liu
  • Lu Chen
  • Hao Wu
  • Lei Yin
  • Xin-Gang CuiEmail author
  • Dan-Feng XuEmail author
  • Wen-Hui LiuEmail author
Original Article – Clinical Oncology

Abstract

Purpose

Prostate cancer is one of the leading causes of cancer death for male. In the present study, we applied an integrated bioinformatics approach to provide a novel perspective and identified some hub genes of prostate cancer.

Method

Microarray data of fifty-nine prostate cancer were downloaded from Gene Expression Omnibus. Gene Ontology and pathway analysis were applied for differentially expressed genes between high and low grade prostate cancer. Weighted gene coexpression network analysis was applied to construct gene network and classify genes into different modules. The most related module to high grade prostate cancer was identified and hub genes in the module were revealed. Ingenuity pathway analysis was applied to check the chosen module’s relationship to high grade prostate cancer. Hub gene’s expression profile was verified with clinical samples and a dataset from The Cancer Genome Atlas project.

Result

3193 differentially expressed genes were filtered and gene ontology and pathway analysis revealed some cancer- and sex hormone-related results. Weighted gene coexpression network was constructed and genes were classified into six modules. The red module was selected and ingenuity pathway analysis confirmed its relationship with high grade prostate cancer. Hub genes were identified and their expression profile was also confirmed.

Conclusion

The present study applied integrate bioinformatics approaches to generate a holistic view of high grade prostate cancer and identified hub genes could serve as prognosis markers and potential treatment targets.

Keywords

Prostate cancer WGCNA Prognostic marker Gene ontology Pathway analysis Hub gene 

Notes

Acknowledgements

This work was supported by Grants from the National Natural Science Foundation of China (Nos. 81172191; 81602238); the General Program of Shanghai Municipal Commission of Health and Family Planning (No. 201440511); The Key Basic Research Foundation of Shanghai Committee of Science and Technology of China (No. 14JC1491200).

Compliance with ethical standards

Conflict of interest

The authors declare no potential conflicts of interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the ethics committee of Shanghai Changzheng Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Funding

No funding was received.

Informed consent

Written informed consent was exempted because of the retrospective study design.

Supplementary material

432_2017_2497_MOESM1_ESM.tif (2.9 mb)
Supplementary material 1 (TIFF 2979 kb)
432_2017_2497_MOESM2_ESM.tif (551 kb)
Supplementary material 2 (TIFF 550 kb)
432_2017_2497_MOESM3_ESM.tif (16.2 mb)
Supplementary material 3 (TIFF 16602 kb)
432_2017_2497_MOESM4_ESM.xlsx (10 kb)
Supplementary material 4 (XLSX 9 kb)
432_2017_2497_MOESM5_ESM.xlsx (14 kb)
Supplementary material 5 (XLSX 14 kb)
432_2017_2497_MOESM6_ESM.xlsx (351 kb)
Supplementary material 6 (XLSX 351 kb)

References

  1. Ashburner M, Ball CA, Blake JA et al (2000) Gene ontology: tool for the unification of biology. Nat Genet 25:25–29. doi: 10.1038/75556 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Assinder SJ, Dong Q, Kovacevic Z, Richardson DR (2009) The TGF-β, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J 417:411–421. doi: 10.1042/BJ20081610 CrossRefPubMedGoogle Scholar
  3. Barabasi A-L (2009) Scale-free networks: a decade and beyond. Science (80-) 325:412–413. doi: 10.1126/science.1173299 CrossRefGoogle Scholar
  4. Bi D, Ning H, Liu S et al (2015) Gene expression patterns combined with network analysis identify hub genes associated with bladder cancer. Comput Biol Chem 56:71–83. doi: 10.1016/j.compbiolchem.2015.04.001 CrossRefPubMedGoogle Scholar
  5. Bibikova M, Chudin E, Arsanjani A et al (2007) Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics 89:666–672. doi: 10.1016/j.ygeno.2007.02.005 CrossRefPubMedGoogle Scholar
  6. Bindea G, Mlecnik B, Hackl H et al (2009) ClueGO: a cytoscape plug-into decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25:1091–1093. doi: 10.1093/bioinformatics/btp101 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Blake JA, Christie KR, Dolan ME et al (2015) Gene ontology consortium: going forward. Nucleic Acids Res 43:D1049–D1056. doi: 10.1093/nar/gku1179 CrossRefGoogle Scholar
  8. Castilla C, Flores ML, Medina R et al (2014) Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin PTTG1. Mol Cancer Ther 13(10):2372–2383. doi: 10.1158/1535-7163.MCT-13-0405 CrossRefPubMedGoogle Scholar
  9. Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. doi: 10.1158/2159-8290.CD-12-0095 CrossRefPubMedGoogle Scholar
  10. Chen Z, Zhang C, Wu D et al (2011) Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J 30:2405–2419. doi: 10.1038/emboj.2011.154 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Chiang YT, Wang K, Fazli L et al (2014) GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget 5:451–461CrossRefPubMedPubMedCentralGoogle Scholar
  12. Choi J-W, Kim Y, Lee J-H, Kim Y-S (2013) High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch 463:681–687. doi: 10.1007/s00428-013-1473-6 CrossRefPubMedGoogle Scholar
  13. Cui W, Qian Y, Zhou X et al (2015) Discovery and characterization of long intergenic non-coding RNAs (lincRNA) module biomarkers in prostate cancer: an integrative analysis of RNA-Seq data. BMC Genomics 16:S3. doi: 10.1186/1471-2164-16-S7-S3 CrossRefPubMedPubMedCentralGoogle Scholar
  14. Cuzick J, Swanson GP, Fisher G et al (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12:245–255. doi: 10.1016/S1470-2045(10)70295-3 CrossRefPubMedPubMedCentralGoogle Scholar
  15. de Resende MF, Vieira S, Chinen LT et al (2013) Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med 11:36CrossRefPubMedPubMedCentralGoogle Scholar
  16. Erho N, Crisan A, Vergara IA et al (2013) Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 8:e66855. doi: 10.1371/journal.pone.0066855 CrossRefPubMedPubMedCentralGoogle Scholar
  17. Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1. doi: 10.1126/scisignal.2004088 CrossRefPubMedPubMedCentralGoogle Scholar
  18. Ghazalpour A, Doss S, Zhang B et al (2006) Integrating genetic and network analysis to characterize genes related to mouse weight. PLoS Genet 2:1182–1192. doi: 10.1371/journal.pgen.0020130 CrossRefGoogle Scholar
  19. Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50:125–128PubMedGoogle Scholar
  20. Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64CrossRefPubMedGoogle Scholar
  21. Huang DW, Lempicki RA, Sherman BT (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44–57. doi: 10.1038/nprot.2008.211 CrossRefGoogle Scholar
  22. Huang S, Liao Q, Li L, Xin D (2014) PTTG1 inhibits SMAD3 in prostate cancer cells to promote their proliferation. Tumour Biol 35:6265–6270CrossRefPubMedGoogle Scholar
  23. Kanehisa M, Furumichi M, Tanabe M et al (2017) KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45:D353–D361. doi: 10.1093/nar/gkw1092 CrossRefPubMedGoogle Scholar
  24. Khatri P, Sirota M, Butte AJ (2012) Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol. doi: 10.1371/journal.pcbi.1002375 PubMedPubMedCentralGoogle Scholar
  25. Khongkow P, Gomes AR, Gong C et al (2016) Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene 35:990–1002. doi: 10.1038/onc.2015.152 CrossRefPubMedGoogle Scholar
  26. Kidokoro T, Tanikawa C, Furukawa Y et al (2008) CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27:1562–1571. doi: 10.1038/sj.onc.1210799 CrossRefPubMedGoogle Scholar
  27. Kim Y, Choi J-W, Lee J-H, Kim Y-S (2014) MAD2 and CDC20 are upregulated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix. Int J Gynecol Pathol 33:517–523. doi: 10.1097/PGP.0000000000000082 CrossRefPubMedGoogle Scholar
  28. Kirk JS, Schaarschuch K, Dalimov Z et al (2015) Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget 6:3136–3146CrossRefPubMedGoogle Scholar
  29. Kuner R, Fälth M, Pressinotti NC et al (2013) The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. J Mol Med 91:237–248. doi: 10.1007/s00109-012-0949-1 CrossRefPubMedGoogle Scholar
  30. Langfelder P, Horvath S (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinform 9:559. doi: 10.1186/1471-2105-9-559 CrossRefGoogle Scholar
  31. Langfelder P, Zhang B, Horvath S (2008) Defining clusters from a hierarchical cluster tree: the dynamic tree cut package for R. Bioinformatics 24:719–720. doi: 10.1093/bioinformatics/btm563 CrossRefPubMedGoogle Scholar
  32. Lee B, Mazar J, Aftab MN et al (2014) Long noncoding RNAs as putative biomarkers for prostate cancer detection. J Mol Diagn 16:615–626. doi: 10.1016/j.jmoldx.2014.06.009 CrossRefPubMedPubMedCentralGoogle Scholar
  33. Li K, Mao Y, Lu L et al (2016) Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel. Int J Oncol 49:1679–1685. doi: 10.3892/ijo.2016.3671 PubMedGoogle Scholar
  34. Loeb S, Bruinsma SM, Nicholson J et al (2015) Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol 67:619–626. doi: 10.1016/j.eururo.2014.10.010 CrossRefPubMedGoogle Scholar
  35. Ma R, Kang X, Zhang G et al (2016) High expression of UBE2C is associated with the aggressive progression and poor outcome of malignant glioma. Oncol Lett 11:2300–2304. doi: 10.3892/ol.2016.4171 PubMedPubMedCentralGoogle Scholar
  36. MacLennan NK, Dong J, Aten JE et al (2009) Weighted gene co-expression network analysis identifies biomarkers in glycerol kinase deficient mice. Mol Genet Metab 98:203–214. doi: 10.1016/j.ymgme.2009.05.004 CrossRefPubMedGoogle Scholar
  37. Malki K, Tosto MG, Jumabhoy I et al (2013) Integrative mouse and human mRNA studies using WGCNA nominates novel candidate genes involved in the pathogenesis of major depressive disorder research article. Pharmacogenomics 14:1979–1990. doi: 10.2217/pgs.13.154 CrossRefPubMedGoogle Scholar
  38. Mao Y, Li K, Lu L et al (2016) Overexpression of Cdc20 in clinically localized prostate cancer: relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy. Cancer Biomark 16:351–358CrossRefPubMedGoogle Scholar
  39. Mason MJ, Fan G, Plath K et al (2009) Signed weighted gene co-expression network analysis of transcriptional regulation in murine embryonic stem cells. BMC Genom 10:327. doi: 10.1186/1471-2164-10-327 CrossRefGoogle Scholar
  40. Moura IMB, Delgado ML, Silva PMA et al (2014) High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med 43:225–231. doi: 10.1111/jop.12115 CrossRefPubMedGoogle Scholar
  41. Murphy AJ, Hughes CA, Barrett C et al (2007) Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res 67:2893–2898CrossRefPubMedGoogle Scholar
  42. Psyrri A, Kalogeras KT, Kronenwett R et al (2012) Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Ann Oncol 23:1422–1427. doi: 10.1093/annonc/mdr527 CrossRefPubMedGoogle Scholar
  43. Puniya BL, Kulshreshtha D, Verma SP et al (2013) Integrated gene co-expression network analysis in the growth phase of Mycobacterium tuberculosis reveals new potential drug targets. Mol BioSyst 9:2798–2815. doi: 10.1039/c3mb70278b CrossRefPubMedGoogle Scholar
  44. R Core Team (2017) R: a language and environment for statistical computingGoogle Scholar
  45. Shannon P, Markiel A, Ozier O et al (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13:2498–2504. doi: 10.1101/gr.1239303 CrossRefPubMedPubMedCentralGoogle Scholar
  46. Shen Z, Jiang X, Zeng C et al (2013) High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression. BMC Cancer 13:192. doi: 10.1186/1471-2407-13-192 CrossRefPubMedPubMedCentralGoogle Scholar
  47. Shuliang S, Lei C, Guangwu J, Changjie L (2013) Involvement of ubiquitin-conjugating enzyme E2C in proliferation and invasion of prostate carcinoma cells. Oncol Res 21:121–127. doi: 10.3727/096504013X13832473329953 CrossRefPubMedGoogle Scholar
  48. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66:7–30. doi: 10.3322/caac.21332 CrossRefPubMedGoogle Scholar
  49. Stangel D, Erkan M, Buchholz M et al (2015) Kif20a inhibition reduces migration and invasion of pancreatic cancer cells. J Surg Res 197:91–100. doi: 10.1016/j.jss.2015.03.070 CrossRefPubMedGoogle Scholar
  50. Stark JR, Perner S, Stampfer MJ et al (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27:3459–3464. doi: 10.1200/JCO.2008.20.4669 CrossRefPubMedPubMedCentralGoogle Scholar
  51. Taniuchi K, Furihata M, Saibara T (2014) KIF20A-mediated RNA granule transport system promotes the invasiveness of pancreatic cancer cells. Neoplasia 16:1082–1093. doi: 10.1016/j.neo.2014.10.007 CrossRefPubMedPubMedCentralGoogle Scholar
  52. Wan X, Huang W, Yang S et al (2016) Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer. Oncotarget 7:60503–60518. doi: 10.18632/oncotarget.11391 CrossRefPubMedPubMedCentralGoogle Scholar
  53. Wang Q, Li W, Zhang Y et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245–256. doi: 10.1016/j.cell.2009.04.056 CrossRefPubMedPubMedCentralGoogle Scholar
  54. Wang H, Zhang C, Rorick A et al (2011) CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability. Cancer Res 71:4866–4876. doi: 10.1158/0008-5472.CAN-10-4576 CrossRefPubMedPubMedCentralGoogle Scholar
  55. Wang L, Gong Y, Chippada-Venkata U et al (2015) A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Med 13:201CrossRefPubMedPubMedCentralGoogle Scholar
  56. Yan G-R, Zou F-Y, Dang B-L et al (2012) Genistein-induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study. Proteomics 12:2391–2399. doi: 10.1002/pmic.201100652 CrossRefPubMedGoogle Scholar
  57. Zhang S, Cao J (2009) A close examination of double filtering with fold change and T test in microarray analysis. BMC Bioinform 10:402. doi: 10.1186/1471-2105-10-402 CrossRefGoogle Scholar
  58. Zhang B, Genetics H, Zhang B, Horvath S (2005) A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. doi: 10.2202/1544-6115.1128 PubMedGoogle Scholar
  59. Zhang W, He W, Shi Y et al (2016) High expression of KIF20A is associated with poor overall survival and tumor progression in early-stage cervical squamous cell carcinoma. PLoS One 11:e0167449. doi: 10.1371/journal.pone.0167449 CrossRefPubMedPubMedCentralGoogle Scholar
  60. Zhao S, Geybels MS, Leonardson A et al (2016) Epigenome-wide tumor DNA methylation profiling identifies novel prognostic biomarkers of metastatic-lethal progression in men with clinically localized prostate cancer. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-16-0549 Google Scholar
  61. Zhu X, Mao Z, Na Y et al (2006) Significance of pituitary tumor transforming gene 1 (PTTG1) in prostate cancer. Anticancer Res 26:1253–1259PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of Urinary Surgery, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiChina
  2. 2.Department of Urinary Surgery, Changzheng HospitalSecond Military Medical UniversityShanghaiChina
  3. 3.National Center for Liver CancerShanghaiChina
  4. 4.Department of Urinary Surgery, Changhai HospitalSecond Military Medical UniversityShanghaiChina
  5. 5.BGI-WuhanWuhan BGI Clinical Laboratory Limited CompanyWuhanChina
  6. 6.Department of Urinary Surgery, Third Affiliated HospitalSecond Military Medical UniversityShanghaiChina
  7. 7.Department of Plastic and Reconstructive Surgery, Shanghai Ninth People’s HospitalShanghai Jiao Tong University School of MedicineShanghaiChina

Personalised recommendations